当前位置: X-MOL 学术Lancet Neurol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Corrections
The Lancet Neurology ( IF 46.5 ) Pub Date : 2018-01-01 , DOI: 10.1016/s1474-4422(17)30428-3


Gilhus N E. Eculizumab: a treatment option for myasthenia gravis? Lancet Neurol 2017; 16: 947–48—The original title of this comment was “Eculizumab: a treatment option for mysthenia gravis?”. This title has been corrected to “Eculizumab: a treatment option for myasthenia gravis?”. This correction has been made to the online version as of Dec 15, 2017.

中文翻译:

更正

Gilhus N E. Eculizumab:重症肌无力的治疗选择吗?柳叶刀神经科学2017; 16: 947–48 —该评论的原始标题为“依库丽单抗:重症肌无力的治疗选择?”。此标题已更正为“ Eculizumab:重症肌无力的治疗选择?”。自2017年12月15日起已对在线版本进行了更正。
更新日期:2017-12-16
down
wechat
bug